JPMorgan Raises Eli Lilly (LLY) Price Target to $1,400

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.8% in the afternoon session after JPMorgan's Chris Schott raised his price target to $1,400 from $1,300, reiterating an Overweight rating.

Rating Change

JPMorgan increased its price target for Eli Lilly by approximately 7.7%, from $1,300 to $1,400, while maintaining an Overweight rating, signaling a bullish outlook.

Analyst Rationale

Analyst Chris Schott believes Eli Lilly has a strong product portfolio, particularly in diabetes and obesity treatments (Mounjaro/Zepbound), which supports future growth prospects. The company's promising pipeline also justifies the higher target.

Context

The update follows a strong performance for Eli Lilly over the past year, with the stock gaining over 50%, driven by robust sales of diabetes and obesity drugs. Other analysts, including those from Goldman Sachs and Morgan Stanley, also hold positive ratings on the stock, with price targets ranging from $1,350 to $1,500.

What to Make of It

The price target hike from JPMorgan reflects analyst confidence in Eli Lilly's ability to sustain growth, especially amid rising demand for diabetes and obesity treatments. However, investors should consider potential risks such as competition and regulatory pricing.